5,9-diethoxy-7-(4-(hydroxymethyl)-2-methylphenyl)-7,8-dihydro-6H-pyrrolo[3,4-g]quinolin-6-one | 1271213-33-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5,9-diethoxy-7-(4-(hydroxymethyl)-2-methylphenyl)-7,8-dihydro-6H-pyrrolo[3,4-g]quinolin-6-one
• CAS: 1271213-33-2
• 化学式: C₂₃H₂₄N₂O₄
• 分子量: 392.455
• InChiKey: PYPNOWCLFLYEHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.99
• 重原子数：
  29.0
• 可旋转键数：
  6.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  71.89
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  5,9-diethoxy-7-(4-(hydroxymethyl)-2-methylphenyl)-7,8-dihydro-6H-pyrrolo[3,4-g]quinolin-6-one 在 dimethyl sulfide borane 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 7-(4-(2-aminoethyl)-2-methylphenyl)-5,9-diethoxy-7,8-dihydro-6H-pyrrolo[3,4-g]quinolin-6-one
  参考文献：
  名称：

  Naphthalene/quinoline amides and sulfonylureas as potent and selective antagonists of the EP4 receptor

  摘要：

  Two new series of EP4 antagonists based on naphthalene/quinoline scaffolds have been identified as part of our on-going efforts to develop treatments for inflammatory pain. One series contains an acidic sulfonylurea pharmacophore, whereas the other is a neutral amide. Both series show subnanomolar intrinsic binding potency towards the EP4 receptor, and excellent selectivity towards other prostanoid receptors. While the amide series generally displays poor pharmacokinetic parameters, the sulfonylureas exhibit greatly improved profile. MF-592, the optimal compound from the sulfonylurea series, has a desirable overall preclinical profile that suggests it is suitable for further development. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.014
• 作为产物：
  描述：

  4-氨基-3-甲基苯甲酸甲酯 在 三乙基硅烷 、 sodium tetrahydroborate 、 dimethyl sulfide borane 、 水 、 溶剂黄146 、 三氟乙酸 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 生成 5,9-diethoxy-7-(4-(hydroxymethyl)-2-methylphenyl)-7,8-dihydro-6H-pyrrolo[3,4-g]quinolin-6-one
  参考文献：
  名称：

  Naphthalene/quinoline amides and sulfonylureas as potent and selective antagonists of the EP4 receptor

  摘要：

  Two new series of EP4 antagonists based on naphthalene/quinoline scaffolds have been identified as part of our on-going efforts to develop treatments for inflammatory pain. One series contains an acidic sulfonylurea pharmacophore, whereas the other is a neutral amide. Both series show subnanomolar intrinsic binding potency towards the EP4 receptor, and excellent selectivity towards other prostanoid receptors. While the amide series generally displays poor pharmacokinetic parameters, the sulfonylureas exhibit greatly improved profile. MF-592, the optimal compound from the sulfonylurea series, has a desirable overall preclinical profile that suggests it is suitable for further development. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.014